CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 76% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English
Country • Select Country
    Entity • The products and services listed on this website are not available to US residents.
    English العَرَبِيَّة Deutsch ελληνικά Español Français Italiano Magyar Nederlands Polski Română Русский 简体中文 繁體中文

    Trade NeuroBo Pharmaceuticals, Inc. - NRBO CFD

    Market is not available at the moment

    Market information is presented
    as of 2023-09-21

    • Summary
    Trading Conditions
    Spread -
    Long position overnight fee

    Long position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee -0.026151 %
    Charges from full value of position ($-4.97)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		-0.026151%
    Short position overnight fee

    Short position overnight fee

    Margin. Your investment $1,000.00
    Overnight fee 0.003929 %
    Charges from full value of position ($0.75)
    Trade size with leverage ~ $20,000.00
    Money from leverage ~ $19,000.00
    Go to platform
    		0.003929%
    Overnight fee time 21:00 (UTC)
    Min traded quantity 1
    Currency USD
    Margin 5%
    Stock exchange United States of America
    Commission on trade 0%

    *Information provided by Capital.com

    Neurobo Pharmaceuticals Inc ESG Risk Ratings

    High Medium Low Negligible

    ‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.

    More ESG coverage

    Key Stats
    Prev. Close* N/A
    Open* N/A
    1-Year Change* N/A
    Day's Range* N/A
    52 wk Range 0.36-63.85
    Average Volume (10 days) 132.33K
    Average Volume (3 months) 8.10M
    Market Cap 17.60M
    P/E Ratio -100.00K
    Shares Outstanding 38.43M
    Revenue N/A
    EPS -4.23
    Dividend (Yield %) N/A
    Beta 0.02
    Next Earnings Date Nov 13, 2023

    All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

    Date Close Change Change (%) Open High Low

    NeuroBo Pharmaceuticals, Inc. Events

    Time (UTC) Country Event
    Monday, November 13, 2023

    Time (UTC)

    21:00

    Country

    US

    Event

    Q3 2023 Neurobo Pharmaceuticals Inc Earnings Release
    Q3 2023 Neurobo Pharmaceuticals Inc Earnings Release

    Forecast

    -

    Previous

    -
    View all events
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total revenue 0 0 0 0 0
    Total Operating Expense 19.628 15.298 29.716 21.29 22.805
    Selling/General/Admin. Expenses, Total 8.64 8.752 7.846 2.701 8.493
    Research & Development 2.778 6.546 4.531 5.324 14.312
    Unusual Expense (Income) 8.21 0 17.339 13.265
    Operating Income -19.628 -15.298 -29.716 -21.29 -22.805
    Interest Income (Expense), Net Non-Operating -2.191 0.014 0.039 -0.022 -0.654
    Other, Net 7.852 0 -0.001 0 -0.178
    Net Income Before Taxes -13.967 -15.284 -29.678 -21.312 -23.637
    Net Income After Taxes -13.967 -15.284 -29.678 -21.312 -23.637
    Net Income Before Extra. Items -13.967 -15.284 -29.678 -21.312 -23.637
    Net Income -13.967 -15.284 -29.678 -21.312 -23.637
    Total Adjustments to Net Income
    Income Available to Common Excl. Extra. Items -13.967 -15.284 -29.678 -21.312 -23.637
    Income Available to Common Incl. Extra. Items -13.967 -15.284 -29.678 -21.312 -23.637
    Diluted Net Income -13.967 -15.284 -29.678 -21.312 -23.637
    Diluted Weighted Average Shares 2.57362 0.77138 0.54052 0.17412 0.01841
    Diluted EPS Excluding Extraordinary Items -5.42698 -19.8138 -54.906 -122.397 -1284.23
    Dividends per Share - Common Stock Primary Issue 0
    Diluted Normalized EPS -2.23692 -19.8138 -22.8279 -46.2148 -1284.23
    Total Extraordinary Items
    Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
    Total revenue 0 0 0 0 0
    Total Operating Expense 3.806 2.52 10.43 3.104 3.219
    Selling/General/Admin. Expenses, Total 1.442 1.883 1.915 2.533 2.237
    Research & Development 2.364 0.637 0.305 0.571 0.982
    Operating Income -3.806 -2.52 -10.43 -3.104 -3.219
    Interest Income (Expense), Net Non-Operating -2.191 0 0
    Other, Net 3.072 -0.084 7.945 -0.009 -0.084
    Net Income Before Taxes -0.734 -2.604 -4.676 -3.113 -3.303
    Net Income After Taxes -0.734 -2.604 -4.676 -3.113 -3.303
    Net Income Before Extra. Items -0.734 -2.604 -4.676 -3.113 -3.303
    Net Income -0.734 -2.604 -4.676 -3.113 -3.303
    Income Available to Common Excl. Extra. Items -0.734 -2.604 -4.676 -3.113 -3.303
    Income Available to Common Incl. Extra. Items -0.734 -2.604 -4.676 -3.113 -3.303
    Diluted Net Income -0.734 -2.604 -4.676 -3.113 -3.303
    Diluted Weighted Average Shares 40.472 27.1767 7.62842 0.88869 0.88873
    Diluted EPS Excluding Extraordinary Items -0.01814 -0.09582 -0.61297 -3.5029 -3.71656
    Dividends per Share - Common Stock Primary Issue 0 0 0 0
    Diluted Normalized EPS -0.01814 -0.09582 0.46327 -3.5029 -3.71656
    Unusual Expense (Income) 8.21
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Total Current Assets 33.532 16.584 10.683 14.118 19.686
    Cash and Short Term Investments 33.364 16.387 10.089 13.908 18.954
    Cash & Equivalents 33.364 16.387 10.089 13.908 18.954
    Prepaid Expenses 0.168 0.197 0.546 0.153 0.715
    Total Assets 33.534 16.799 10.968 14.468 19.694
    Other Long Term Assets, Total 0.008
    Total Current Liabilities 11.784 2.157 3.695 2.082 11.919
    Accounts Payable 0.708 0.83 2.575 0.638 2.044
    Accrued Expenses 0.28 1.327 1.12 1.444 0.438
    Notes Payable/Short Term Debt 0 0 0 0 0
    Other Current Liabilities, Total 10.796
    Total Liabilities 11.784 2.202 3.765 2.176 11.92
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0 0.045 0.07 0.094 0.001
    Total Equity 21.75 14.597 7.203 12.292 7.774
    Common Stock 0.025 0.027 0.02 0.016 0.022
    Additional Paid-In Capital 117.52 96.394 73.713 49.13 91.863
    Retained Earnings (Accumulated Deficit) -95.795 -81.828 -66.544 -36.866 -84.111
    Total Liabilities & Shareholders’ Equity 33.534 16.799 10.968 14.468 19.694
    Total Common Shares Outstanding 25.436 0.88864 0.65564 0.51971 0.01902
    Other Current Assets, Total 0 0.048 0.057 0.017
    Current Port. of LT Debt/Capital Leases 9.437
    Long Term Debt 0 0
    Property/Plant/Equipment, Total - Net 0.002 0.215 0.285 0.35
    Property/Plant/Equipment, Total - Gross 0.03 0.326 0.348 0.367
    Accumulated Depreciation, Total -0.028 -0.111 -0.063 -0.017
    Other Equity, Total 0 0.004 0.014 0.012
    Preferred Stock - Non Redeemable, Net 0
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Total Current Assets 31.483 33.532 7.554 10.077 13.264
    Cash and Short Term Investments 30.813 33.364 6.356 8.849 11.557
    Cash & Equivalents 30.813 33.364 6.356 8.849 11.557
    Prepaid Expenses 0.67 0.168 0.859 1.228 1.707
    Other Current Assets, Total 0.339
    Total Assets 31.488 33.534 7.557 10.082 13.461
    Property/Plant/Equipment, Total - Net 0.005 0.002 0.003 0.005 0.197
    Property/Plant/Equipment, Total - Gross 0.034 0.03 0.03 0.03 0.32
    Accumulated Depreciation, Total -0.029 -0.028 -0.027 -0.025 -0.123
    Total Current Liabilities 10.98 11.784 1.619 1.249 1.496
    Accounts Payable 1.119 0.708 1.075 0.664 0.776
    Accrued Expenses 0.417 0.28 0.544 0.585 0.72
    Notes Payable/Short Term Debt 0 0 0 0 0
    Total Liabilities 10.98 11.784 1.619 1.249 1.533
    Total Long Term Debt 0 0 0 0 0
    Other Liabilities, Total 0 0 0 0.037
    Total Equity 20.508 21.75 5.938 8.833 11.928
    Common Stock 0.027 0.025 0.001 0.027 0.027
    Additional Paid-In Capital 118.88 117.52 97.056 96.812 96.601
    Retained Earnings (Accumulated Deficit) -98.399 -95.795 -91.119 -88.006 -84.703
    Other Equity, Total 0 0 0 0.003
    Total Liabilities & Shareholders’ Equity 31.488 33.534 7.557 10.082 13.461
    Total Common Shares Outstanding 27.1767 25.436 0.88869 0.88864 0.88864
    Preferred Stock - Non Redeemable, Net 0 0 0 0
    Other Current Liabilities, Total 9.444 10.796
    • Annual
    • Quarterly
    2022 2021 2020 2019 2018
    Net income/Starting Line -13.967 -15.284 -29.678 -21.312 -15.529
    Cash From Operating Activities -11.712 -15.134 -10.764 -7.039 -14.451
    Non-Cash Items 3.403 0.686 18.059 13.512 1.856
    Cash Taxes Paid 0 0 0
    Cash Interest Paid 0 0.001 0
    Changes in Working Capital -1.168 -0.584 0.809 0.744 -0.778
    Cash From Financing Activities 28.681 22.026 6.858 24.167 17.246
    Financing Cash Flow Items -3.569 -2.089 -0.695 -0.074 -0.054
    Issuance (Retirement) of Stock, Net 32.25 24.115 7.553 24.241 16.8
    Issuance (Retirement) of Debt, Net 0 0.5
    Net Change in Cash 16.977 6.298 -3.834 11.078 2.795
    Cash From Operating Activities 0.02 0.048 0.046 0.017 0
    Cash From Investing Activities 0.008 -0.586 0.069 -6.057 -0.003
    Capital Expenditures 0 -0.003 -0.004 -0.214 -0.003
    Other Investing Cash Flow Items, Total 0.008 -0.583 0.073 -5.843 0
    Foreign Exchange Effects 0 -0.008 0.003 0.007 0.003
    Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
    Net income/Starting Line -2.604 -13.967 -9.291 -6.178 -2.875
    Cash From Operating Activities -2.547 -11.712 -9.905 -7.546 -4.829
    Cash From Operating Activities 0.001 0.02 0.019 0.017 0.012
    Non-Cash Items 0.01 3.403 0.719 0.501 0.213
    Cash Taxes Paid
    Cash Interest Paid
    Changes in Working Capital 0.046 -1.168 -1.352 -1.886 -2.179
    Cash From Investing Activities -0.004 0.008 0.008 0.008 0
    Capital Expenditures -0.004 0 0
    Cash From Financing Activities 0 28.681 -0.134 0 0
    Financing Cash Flow Items 0 -3.569 -0.134 0 0
    Issuance (Retirement) of Stock, Net 32.25 0 0 0
    Foreign Exchange Effects 0 0 0 0 -0.001
    Net Change in Cash -2.551 16.977 -10.031 -7.538 -4.83
    Other Investing Cash Flow Items, Total 0.008 0.008 0.008 0

    NeuroBo Pharmaceuticals, Inc. Company profile

    NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for coronavirus, neurodegenerative, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which has completed Phase 2 clinical trial to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Boston, Massachusetts.
    Industry: Bio Therapeutic Drugs

    200 Berkeley St.
    Fl 19
    BOSTON
    MASSACHUSETTS 02116
    US

    News

    EUR/USD tests key support

    EUR/USD is currently testing a key support level after the Federal Reserve indicated a potential extension of higher interest rates.

    14:32, 21 September 2023
    Bank of England building

    BoE leaves rates unchanged, GBP drops further as investors look for more clarity

    The Bank of England has left rates unchanged at 5.25% with a 5-4 vote split after CPI dropped more than expected in August

    11:45, 21 September 2023
    British banknotes and coins photographed directly above. The coins are in a stack, placed on top of the banknotes.

    GBP softer after CPI surprise, JPY focused on any further hints from Ueda

    GBP drops after a softer CPI reading scares investors about the BoE intentions. JPY on the lookout for further policy tweaks from Governor Ueda.

    12:42, 20 September 2023

    How to Trade The Break & Retest

    In this week's instalment, we delve into the Break & Retest pattern—a strategic approach to navigating breakout trades. If you've wrestled with the frustration of false breakouts, incorporating this pattern into your trading toolkit may help you overcome this challenge and put you on the path to becoming a more confident and consistent trader.

    11:59, 20 September 2023

    Cable coils near lows ahead of Fed and BoE rate decisions

    It’s a big week for Cable (GBP/USD) as both the Federal Reserve and the Bank of England are set to make crucial rate decisions.

    14:16, 19 September 2023

    FTSE 100 Technical Outlook - 18 September 2023

    In prior technical outlooks, we highlighted the importance of staying alert in sleepy markets, and last Thursday’s developments on the FTSE 100 serve as a prime illustration of this principle.

    06:55, 19 September 2023
    View of the City of London’s illuminated financial district skyline at dusk

    Market Analysis: FTSE 100 boosted by ECB rate hike end and iron ore rally

    The FTSE 100 rose over 2% on Thursday as the ECB announced no more rate hikes for now.

    13:46, 15 September 2023

    People also watch

    ETH/USD

    1,601.10 Price
    +0.450% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 5.40

    XRP/USD

    0.52 Price
    +0.510% 1D Chg, %
    Long position overnight fee -0.0753%
    Short position overnight fee 0.0069%
    Overnight fee time 21:00 (UTC)
    Spread 0.01192

    BTC/USD

    26,722.35 Price
    +0.120% 1D Chg, %
    Long position overnight fee -0.0616%
    Short position overnight fee 0.0137%
    Overnight fee time 21:00 (UTC)
    Spread 85.00

    Oil - Crude

    90.20 Price
    +0.960% 1D Chg, %
    Long position overnight fee 0.0349%
    Short position overnight fee -0.0568%
    Overnight fee time 21:00 (UTC)
    Spread 0.030

    Still looking for a broker you can trust?

    Join the 555.000+ traders worldwide that chose to trade with Capital.com

    1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading